For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
What Trump’s vaccine executive order actually does
Yesterday, President Trump signed an executive order directing federal health agencies to revise childhood vaccine recommendations, reducing the number of vaccines recommended for…
Blog
Trump administration decision highlights disastrous Part D redesign
The Trump administration recently announced the end of a demonstration project that was pulled together by the Biden administration as the Inflation Reduction…
Blog
Fauci’s lasting legacy will be the damage he did to science and government
Anthony Fauci isn’t faring well in the court of public opinion. His recently divulged “diary” and subsequent July 29 appearance before the Senate Homeland…
Search Posts
Newsletter
The Competitive Enterprise Institute Daily Update
Issues in the News 1. CONGRESS The House of Representative approves legislation requiring the government to negotiate lower…
Op-Eds
The High Cost of Low Price
Should free market advocates oppose a plan aimed at lowering prescription drug costs? Generally, no. But, when such a plan involves the flexing…
Newsletter
The Competitive Enterprise Institute Daily Update
Issues in the News 1. CONGRESS New Democratic congressmen warn Speaker Pelosi to stick to a politically moderate…
Op-Eds
Eco-Intimidation Bypasses Scientific Debate
Junk science traditionally has been pretty much of an in-your-face phenomenon. Activist-generated scary headlines that are followed by a hysterical rush to adopt new…
Letters
We oppose negotiations on Medicare Part D drug prices
We are deeply concerned about proposed legislation that would lead to negotiation of pharmaceutical prices by the federal government for the new Medicare Part…
Study
A Free Market Agenda for the 110th Congress
Washington, D.C., January 10, 2007—Today the Competitive Enterprise Institute releases its policy recommendations for the new leadership on Capitol Hill: This Liberal Congress Went to…